1. Home
  2. NMFC vs PHAT Comparison

NMFC vs PHAT Comparison

Compare NMFC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Mountain Finance Corporation

NMFC

New Mountain Finance Corporation

N/A

Current Price

$7.03

Market Cap

636.6M

Sector

Finance

ML Signal

N/A

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

N/A

Current Price

$5.73

Market Cap

590.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NMFC
PHAT
Founded
2010
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
636.6M
590.6M
IPO Year
2010
2019

Fundamental Metrics

Financial Performance
Metric
NMFC
PHAT
Price
$7.03
$5.73
Analyst Decision
Hold
Buy
Analyst Count
7
12
Target Price
$8.29
★ $19.64
AVG Volume (30 Days)
638.1K
★ 1.6M
Earning Date
11-02-2026
10-29-2026
Dividend Yield
★ 14.21%
N/A
EPS Growth
N/A
★ 42.72
EPS
★ N/A
N/A
Revenue
N/A
★ $175,110,000.00
Revenue This Year
N/A
$79.63
Revenue Next Year
N/A
$54.71
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 216.93
52 Week Low
$6.48
$5.02
52 Week High
$9.84
$18.31

Technical Indicators

Market Signals
Indicator
NMFC
PHAT
Relative Strength Index (RSI) 56.30 33.59
Support Level $6.82 $5.02
Resistance Level $7.30 $7.72
Average True Range (ATR) 0.15 0.61
MACD 0.06 -0.06
Stochastic Oscillator 90.08 27.17

Price Performance

Historical Comparison
NMFC
PHAT

About NMFC New Mountain Finance Corporation

New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: